KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Gains from Investment Securities (2018 - 2020)

Esperion Therapeutics' Gains from Investment Securities history spans 3 years, with the latest figure at $300000.0 for Q2 2020.

  • For Q2 2020, Gains from Investment Securities fell 94.36% year-over-year to $300000.0; the TTM value through Mar 2020 reached $4.8 million, up 3361.97%, while the annual FY2025 figure was $612000.0, N/A changed from the prior year.
  • Gains from Investment Securities reached $300000.0 in Q2 2020 per ESPR's latest filing, down from $4.8 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $5.3 million in Q2 2019 to a low of $139500.0 in Q1 2019.
  • Average Gains from Investment Securities over 3 years is $3.5 million, with a median of $4.6 million recorded in 2018.
  • Peak YoY movement for Gains from Investment Securities: crashed 96.69% in 2019, then surged 3361.97% in 2020.
  • A 3-year view of Gains from Investment Securities shows it stood at $5.3 million in 2018, then dropped by 11.8% to $4.7 million in 2019, then plummeted by 93.59% to $300000.0 in 2020.
  • Per Business Quant, the three most recent readings for ESPR's Gains from Investment Securities are $300000.0 (Q2 2020), $4.8 million (Q1 2020), and $4.7 million (Q4 2019).